Gilead Sciences
GILD
$156.19
-0.75%
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes therapies for life-threatening infectious diseases and, increasingly, oncology and inflammation, with its franchise anchored in HIV (Biktarvy and the broader HIV portfolio) and hepatitis B/C, supplemented by CAR-T cell therapies Yescarta/Tecartus and Trodelvy. Gilead is the dominant commercial force in HIV treatment and prevention globally, a position that gives it durable, annuity-like cash flows and pricing power that few large-cap biopharmas can match, while its oncology build-out positions it as a platform consolidator rather than a single-asset story. The current investor narrative is a tug-of-war between a strengthening core and a costly pipeline pivot: the Bixlenvo approval and raised 2026 HIV sales guidance have reinforced the growth case, while a string of bolt-on and mid-size deals (Tubulis at roughly $3.15 billion, Ouro Medicines at over $1.5 billion, and the roughly $7.8 billion Arcellx offer for full CAR-T control) plus the termination of the Trodelvy-Keytruda lung cancer study have kept debate focused on capital allocation discipline and oncology execution risk. A Q2 2026 GAAP loss driven by a large one-time acquired in-process R&D charge has muddied headline earnings, sharpening the market's focus on adjusted EPS, free cash flow durability, and whether the acquired assets can offset eventual HIV patent cliffs.…
GILD
Gilead Sciences
$156.19
Related headlines
Investment Opinion: Should I buy GILD Today?
Rating: Buy (moderate conviction). The thesis is that Gilead's HIV annuity — growing 10.2% YoY with Bixlenvo and raised 2026 guidance — plus $13.2B of TTM free cash flow is being valued at only 15.7x forward EPS of $13.21, while 26 analysts carry a buy consensus (mean 1.68) and a $159.85 average target, about 2.3% above the $156.19 price. The stock is a cash-generative defensive compounder whose pipeline investments are not yet reflected in the multiple.
Supporting evidence: forward PE of 15.7x and EV/EBITDA of 12.5x are modest for a company with 78.8% gross margins and a 28.9% net margin; revenue grew 10.2% YoY in Q2 2026 to $7.80B; TTM free cash flow of $13.2B covers the 2.62% dividend at a 47.0% payout ratio; and the stock has outperformed SPY by 17.0 points over one year with a beta of only 0.33. The PEG ratio of 0.01 and PB of 6.73x show the market is paying a premium on book but a discount on earnings growth.
Key risks that could invalidate the thesis are capital allocation discipline (over $12B of deals and a $10.5B Q2 GAAP loss), oncology execution (Trodelvy-Keytruda trial termination), and valuation near the 52-week high of $160.51. The rating would upgrade to a stronger Buy if the Arcellx CAR-T data de-risk the oncology story or if the forward PE compresses below 14x; it would downgrade to Hold if HIV growth decelerates below 5% or if another major acquisition is written down. Verdict: fairly valued to modestly undervalued relative to growth and cash flow, but not a deep-value opportunity at 6.7x book.
Sign up to view all
GILD 12-Month Price Forecast
The forward view is constructive because Gilead combines a durable, growing HIV annuity with a modest 15.7x forward multiple and strong free cash flow, while the analyst consensus target of $159.85 sits just above the current price. The main uncertainty is capital allocation: over $12B of recent deals and a $10.5B Q2 GAAP loss mean the market needs evidence that Arcellx, Tubulis, and Ouro can offset the eventual HIV patent cliff. I would upgrade to high confidence if Arcellx CAR-T data de-risk the oncology story or if adjusted EPS beats consensus, and I would downgrade to neutral if HIV growth falls below 5% or another acquisition is written down. At 2.7% below the 52-week high, the risk/reward is balanced but skewed positive given the low beta and dividend support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $159.85 and implied upside of +2.3% versus the current price.
Average Target
$159.85
0 analysts
Implied Upside
+2.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$126 - $180
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: GILD Investment Factors
The bull case currently has stronger evidence: 10.2% revenue growth, a 28.9% net margin, $13.2B TTM free cash flow, a 2.62% dividend, and 17 points of 1-year relative strength versus SPY all point to a durable, cash-generative franchise trading at only 15.7x forward earnings. The bear case rests on capital allocation risk — a $10.5B Q2 GAAP loss from IPR&D charges and over $12B of acquisitions — plus oncology setbacks and a price near its 52-week high. The single most important tension is whether the acquired oncology and inflammation assets (Arcellx CAR-T, Tubulis, Ouro) can generate returns that offset the eventual HIV patent cliff before the market loses patience with the deal spree. If those assets deliver, the 15.7x forward PE is too cheap; if they disappoint, the stock has limited valuation cushion at 6.7x book.
Bullish
- HIV franchise re-accelerating with Bixlenvo: Q2 2026 revenue of $7.80B grew 10.2% YoY, and the Bixlenvo approval plus raised 2026 HIV sales guidance reinforce the annuity-like HIV cash flow base. This is the core engine that funds the oncology pivot and dividend.
- Analyst consensus buy with 2.3% upside: 26 analysts rate GILD a buy (mean 1.68) with an average target of $159.85 versus the $156.19 close, implying roughly 2.3% upside; the high target of $180 implies 15.2% upside. The low target of $126 is 19.3% below the current price, framing the risk/reward.
- Cheap forward multiple versus growth: Forward PE of 15.7x against consensus FY EPS of $13.21 and a PEG of 0.01 signals the market is pricing little growth despite 10.2% revenue growth and a 28.9% net margin. EV/EBITDA of 12.5x is modest for a large-cap biopharma with 78.8% gross margins.
- Strong relative strength and low beta: GILD is up 32.5% over 1 year versus SPY's 15.5%, a 17.0-point relative strength gap, and up 28.4% YTD versus 11.9% for SPY. Beta of 0.33 makes it a defensive compounder in a volatile tape.
Bearish
- Q2 2026 GAAP loss from IPR&D charge: Q2 2026 EPS was -$8.45 with a net loss of $10.50B, driven by $12.93B of other expenses (acquired IPR&D), versus $1.57 EPS in Q2 2025. Headline earnings are volatile and obscure the underlying adjusted profitability.
- Acquisition spree strains capital discipline: Deals including Tubulis (~$3.15B), Ouro Medicines (>$1.5B), and the ~$7.8B Arcellx offer at a 68% premium total well over $12B, raising integration and write-down risk. Debt-to-equity of 1.10 and a current ratio of 1.55 leave less cushion than peers.
- Oncology execution setbacks: Termination of the Trodelvy-Keytruda lung cancer study in June 2026 highlights pipeline risk in the very segment meant to offset eventual HIV patent cliffs. The market is paying for oncology optionality that has yet to prove out.
- Valuation near 52-week high: At $156.19, GILD trades just 2.7% below its 52-week high of $160.51 and 37.0% above the 52-week low of $114.02. PB of 6.73x and PS of 5.19x are rich for a mature drug manufacturer, limiting margin of safety.
GILD Technical Analysis
Beta
0.33
0.33x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$114-$161
Price range past year
Annual Return
+32.5%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | +5.8% | +0.2% |
| 3m | +16.3% | +2.9% |
| 6m | +13.5% | +8.4% |
| 1y | +32.5% | +14.9% |
| ytd | +28.4% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Quarterly Revenue
$7.8B
2026-06
Revenue YoY Growth
+10.2%
YoY Comparison
Gross Margin
79.8%
Latest Quarter
Free Cash Flow
$13.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and balance-sheet leverage. Q2 2026 produced a GAAP net loss of $10.50B and EPS of -$8.45 because of $12.93B in other expenses tied to acquired IPR&D, so headline earnings are highly volatile even as adjusted EPS remains the market's focus. Debt-to-equity of 1.10 and a current ratio of 1.55 are adequate but not fortress-like given over $12B committed to Tubulis, Ouro, and the Arcellx offer, and the 47.0% payout ratio leaves less room for dividend growth if free cash flow dips from the current $13.2B TTM level. Revenue concentration in HIV remains the key operational vulnerability: the franchise funds everything else, so any pricing pressure or share loss there would hit both earnings and the acquisition strategy simultaneously.
Market and competitive risks are dominated by valuation compression and pipeline execution. At 15.7x forward earnings, 6.73x book, and 5.19x sales, GILD is not cheap for a mature drug manufacturer, and the stock sits just 2.7% below its 52-week high of $160.51 after a 32.5% one-year run. Beta of 0.33 means macro-driven multiple compression is less likely to come from broad market selloffs than from sector-specific rotation out of defensive pharma or disappointment on pipeline news, as seen when the Trodelvy-Keytruda lung cancer trial was terminated in June 2026. The April 2026 100% tariff on imported drugs adds policy uncertainty, and competitive pressure in HIV prevention and CAR-T from larger oncology players could erode the premium the market assigns to Gilead's franchise.
In a worst-case scenario, the Arcellx CAR-T program disappoints in multiple myeloma, Tubulis and Ouro assets require further write-downs, and HIV growth decelerates as competition intensifies — a combination that would force analysts to cut targets and compress the forward multiple toward the low end of the range. The realistic downside is a move toward the 52-week low of $114.02, roughly 27% below the current $156.19, or toward the analyst low target of $126, about 19% below. The stock's max drawdown of -22.03% over the past year shows that a drawdown of this magnitude is well within historical experience, so an investor could lose 20-27% from current levels in an adverse scenario.
FAQ
The most severe risk is capital allocation: over $12B committed to Tubulis, Ouro, and Arcellx, combined with a $10.5B Q2 2026 GAAP loss from IPR&D charges, raises the prospect of write-downs and earnings volatility. Second is oncology execution, highlighted by the June 2026 termination of the Trodelvy-Keytruda lung cancer trial, which undermines the pipeline meant to offset HIV patent cliffs. Third is valuation compression: at 6.73x book and 2.7% below the 52-week high, a re-rating toward the $126 analyst low target would mean roughly 19% downside. Fourth is policy and competitive risk, including the April 2026 100% drug tariff and HIV competition, which could pressure the 78.8% gross margin.
The 12-month forecast has three scenarios: a 50% base case of $155-$165 around the $159.85 analyst average, a 30% bull case of $170-$180 on Bixlenvo and Arcellx success, and a 20% bear case of $114-$126 toward the 52-week low and analyst low target. The base case is most likely and assumes HIV growth near 10%, adjusted EPS meeting the $13.21 consensus, and no major acquisition write-downs. The bull case requires oncology data to de-risk the pipeline, while the bear case is triggered by trial failures, write-downs, or HIV deceleration. The probability-weighted range centers in the mid-$150s, consistent with the current $156.19 price.
GILD trades at 15.7x forward earnings, 17.9x trailing earnings, 5.19x sales, and 12.5x EV/EBITDA, with a PB of 6.73x. Relative to its 28.9% net margin and 10.2% revenue growth, the forward multiple looks modest, and the PEG of 0.01 suggests the market is not paying for growth. However, the 6.73x book and 5.19x sales are premium levels for a mature drug manufacturer, and the stock is only 2.7% below its 52-week high of $160.51. The market appears to be pricing in pipeline execution risk and acquisition integration costs rather than assigning a discount to the core HIV franchise, implying fair value to modest undervaluation on earnings but limited margin of safety on book.
From a risk/reward perspective, GILD offers modest upside to the $159.85 analyst average target (about 2.3%) and 15.2% to the $180 high target, against 19.3% downside to the $126 low target. The valuation at 15.7x forward EPS of $13.21 is reasonable for a company growing revenue 10.2% with a 28.9% net margin and $13.2B in TTM free cash flow. The biggest downside risk is capital allocation: over $12B of deals and a $10.5B Q2 GAAP loss could weigh on sentiment if oncology assets disappoint. It is a good buy for income and defensive-growth investors with a 12-24 month horizon, but less compelling for those seeking deep value at 6.7x book near the 52-week high.
GILD is better suited to long-term holding given its low beta of 0.33, 2.62% dividend yield with a 47.0% payout ratio, and annuity-like HIV cash flows that support a multi-year oncology build-out. The 32.5% one-year gain and 28.4% YTD return show momentum, but the stock's -22.03% max drawdown and GAAP earnings volatility from IPR&D charges make short-term trading risky around deal announcements. Earnings visibility is moderate: adjusted EPS consensus of $13.21 is well established, but pipeline catalysts like Arcellx CAR-T data can swing the stock sharply. A suggested minimum holding period is 18-24 months to allow the acquired assets to prove out and to capture the dividend.